Synergistic effect of granzyme B-azurin fusion protein on breast cancer cells
As one of the most prevalent malignancies, breast cancer still remains a significant risk for public health. Common therapeutic strategies include invasive surgery, chemotherapy and anti-herceptin antibodies. Adverse effects, drug resistance and low efficacy of current therapies necessitates the emergence of more effective platforms. Naturally released by the immune system, granzyme B activates multiple pro-apoptotic pathways by cleaving critical substrates. Bacterial cupredoxin, azurin, selectively targets cancer cells via a p53-dependent pathway. Fused by a linker, GrB-Azurin fusion protein was overexpressed in HEK293T cells, and purified by metal chromatography. SDS–PAGE, Western blotting and ELISA were performed to confirm successful expression, purification and analyze binding properties of the fusion protein. After treatment of various breast cancer cell lines with increasing concentrations of GrB-Azurin, quantitative real-time RT-PCR was used to measure relative expression of p21, Fas and DR5 pro-apoptotic genes. The results of DNA fragmentation and WST-1 cell viability assays indicated significant apoptosis induction in MDA-MB-231, MCF7 and SK-BR-3 cells, while insignificant cytotoxicity was detected on MCF 10A normal breast cells. Herein, we report the development of a novel biotherapeutic against breast cancer. Selective effectiveness of GrB-Azurin fusion protein on different breast cancer cells highlighted the potential of the designed construct as a candidate anti-cancer biodrug.
KeywordsGranzyme B Azurin Breast cancer Fusion protein Targeting
Compliance with ethical standards
Conflict of interest
The authors declare that there is no conflict of interest regarding the publication of this article.
- 9.Bernardes N, Ribeiro AS, Seruca R, Paredes J, Fialho AM (eds.) (2011) Bacterial protein azurin as a new candidate drug to treat untreatable breast cancers. In: ENBENG 2011 1st Portuguese Meeting in Bioengineering (ENBENG). IEEEGoogle Scholar
- 12.Karreci ES, Eskandari SK, Dotiwala F, Routray SK, Kurdi AT, Assaker JP et al (2017) Human regulatory T cells undergo self-inflicted damage via granzyme pathways upon activation. JCI Insight 2:21Google Scholar
- 19.Goto M, Yamada T, Kimbara K, Horner J, Newcomb M, Gupta TD et al (2003) Induction of apoptosis in macrophages by Pseudomonas aeruginosa azurin: tumour-suppressor protein p53 and reactive oxygen species, but not redox activity, as critical elements in cytotoxicity. Mol Microbiol 47(2):549–559Google Scholar
- 25.Medema J, De Jong J, Peltenburg L, Verdegaal E, Gorter A, Bres S et al (2001) Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci USA 98(20):11515–11520Google Scholar
- 26.Gartel AL, Tyner AL (2002) The role of the cyclin-dependent kinase inhibitor p21 in apoptosis 1 supported in part by NIH grant R01 DK56283 (to ALT) for the p21 research and Campus Research Board and Illinois Department of Public Health Penny Severns Breast and Cervical Cancer grants (to ALG). Mol Cancer Ther 1(8):639–649 1(Google Scholar
- 31.Bębenek M, Duś D, Koźlak J (2013) Prognostic value of the Fas/Fas ligand system in breast cancer. Contemp Oncol 17(2):120Google Scholar
- 36.Amoury M, Kolberg K, Pham A-T, Hristodorov D, Mladenov R, Di Fiore S et al (2016) Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model. Cancer Lett 372(2):201–209CrossRefGoogle Scholar
- 38.Schiffer S, Rosinke R, Jost E, Hehmann-Titt G, Huhn M, Melmer G et al (2014) Targeted ex vivo reduction of CD64-positive monocytes in chronic myelomonocytic leukemia and acute myelomonocytic leukemia using human granzyme B-based cytolytic fusion proteins. Int J Cancer 135(6):1497–1508CrossRefGoogle Scholar